During the height of COVID-19, the life science industry had to decide whether to suspend, modify, or cancel their existing clinical trials and had to reprioritize their 2020 pipelines, which of course had been years in the planning.
COVID-19 initially affected the electronic clinical outcome assessment (eCOA) and electronic patient reported outcome (ePRO) components for clinical trials that were ongoing when the pandemic began. However, sponsors who were already using eCOA in their clinical trials may have had an easier time of it, finding it was less of a lift to keep their eCOA data flowing.
In this webinar, Donna M. Mongiello talks about how COVID-19 changed the eCOA/ePRO landscape—the challenges experienced and changes implemented to continue seamless eCOA and ePRO data collection for these trials.
